Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
ZacksThe FDA approves Bristol Myers’ (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.